Faraz Ali Biography and Net Worth

Mr. Ali was most recently chief business officer at REGENXBIO, where he had accountability for corporate development, commercial planning, portfolio strategy, alliance management and corporate communications. Prior to that, he was a vice president at bluebird bio, where he had accountability for new product planning, program management, patient advocacy and external affairs. Mr. Ali also had roles of increasing global commercial leadership at Genzyme Corporation, where he helped launch multiple first-in-class enzyme replacement therapies for rare diseases. He started his career at General Electric, including technical roles at GE Healthcare and business assignments at GE Corporate. Mr. Ali received his MBA. from Harvard Business School and his B.S. from Stanford University.

What is Faraz Ali's net worth?: The estimated net worth of Faraz Ali is at least $347.17 thousand as of May 18th, 2026. Mr. Ali owns 440,014 shares of Tenaya Therapeutics stock worth more than $347,171 as of July 23rd. This net worth estimate does not reflect any other investments that Mr. Ali may own. Learn More about Faraz Ali's net worth.
How do I contact Faraz Ali?: The corporate mailing address for Mr. Ali and other Tenaya Therapeutics executives is , , . Tenaya Therapeutics can also be reached via phone at 650-825-6990 and via email at [email protected]. Learn More on Faraz Ali's contact information.
Has Faraz Ali been buying or selling shares of Tenaya Therapeutics?: Faraz Ali has not been actively trading shares of Tenaya Therapeutics over the course of the past ninety days. Most recently, Faraz Ali sold 3,390 shares of the business's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.79, for a transaction totalling $2,678.10. Following the completion of the sale, the chief executive officer now directly owns 440,014 shares of the company's stock, valued at $347,611.06. Learn More on Faraz Ali's trading history.
Are insiders buying or selling shares of Tenaya Therapeutics?: In the last year, insiders at the sold shares 16 times. They sold a total of 8,631,961 shares worth more than $5,474,511.12. The most recent insider tranaction occured on May, 18th when CEO Faraz Ali sold 3,390 shares worth more than $2,678.10. Insiders at Tenaya Therapeutics own 2.5% of the company. Learn More about insider trades at Tenaya Therapeutics.
Information on this page was last updated on 5/18/2026.

Faraz Ali Insider Trading History at Tenaya Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/18/2026	Sell	3,390	$0.79	$2,678.10	440,014
2/17/2026	Sell	14,862	$0.64	$9,511.68	443,404
11/17/2025	Sell	3,126	$1.33	$4,157.58	299,666
8/18/2025	Sell	14,533	$1.25	$18,166.25	302,792
5/16/2025	Sell	3,189	$0.44	$1,403.16	317,325
3/10/2025	Sell	9,741	$0.54	$5,260.14	320,514
8/16/2024	Sell	9,748	$2.89	$28,171.72	188,331
2/16/2024	Sell	6,358	$5.86	$37,257.88	113,079
8/16/2023	Sell	5,563	$3.81	$21,195.03	119,437

Faraz Ali Buying and Selling Activity at Tenaya Therapeutics

Tenaya Therapeutics Company Overview

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Today's Range

Now: $0.79

$0.77

$0.80

50 Day Range

MA: $0.78

$0.68

$0.94

2 Week Range

Now: $0.79

$0.53

$2.35

Volume

520,657 shs

Average Volume

3,873,437 shs

Market Capitalization

$170.35 million

P/E Ratio

N/A

Dividend Yield